‘We’re not ready’: US lags on pandemic preparedness after Covid, experts say

The article argues that the US remains unprepared for the next major outbreak, citing weakened testing capacity, outbreak response systems, and public trust after Covid. It highlights ongoing misinformation risks, reduced funding for public health, and setbacks in vaccine equity and global coordination, including pressure on the WHO. While not an immediate market shock, the piece signals persistent policy and healthcare-sector risks tied to future pandemic readiness.

Analysis

The investment angle is not the headline pathogen risk; it is the continued erosion of institutional capacity that turns otherwise containable outbreaks into recurring policy shocks. That favors firms with defensible positions in diagnostics, lab automation, and vaccine manufacturing capacity, while pressuring businesses that rely on public-sector execution to monetize outbreaks quickly. The second-order winner is not a single vaccine maker but the pick-and-shovel layer: sample transport, PCR/rapid testing infrastructure, cold-chain logistics, and CDMO capacity that can scale without depending on federal coordination.

A key market miss is that public-health dysfunction creates a more fragmented, state-led procurement regime. That should improve pricing power for companies with direct state and hospital relationships, but it also lengthens sales cycles and reduces the probability of a single, broad federal stockpiling wave. In practice, that means “pandemic optionality” gets repriced away from speculative small caps and toward revenue-backed incumbents with reimbursement, distribution, and manufacturing certainty. Biotech names tied to misinformation-sensitive adoption may face a slower demand curve even when their science is sound.

The tail risk is not a COVID-style equity drawdown from the outbreak itself; it is a policy-market event if another response failure exposes shortages in tests, syringes, or public-health staffing. That would likely catalyze a short-lived bid in diagnostics and vaccine infrastructure over days to weeks, followed by a broader de-risking if the event turns into a governance story. The contrarian view is that the current gloom may be too broad: pandemic-preparedness spending is cyclical, but the secular need for rapid testing, decentralized manufacturing, and biosurveillance is not disappearing, so the best longs are cash-generative enablers rather than headline-driven vaccine stories.

Key Decisions for Investors

• Build a starter long in TMO and DHR over the next 2-6 weeks on weakness; these are the cleanest picks-and-shovels beneficiaries if states and hospital systems continue to bypass federal bottlenecks. Target is modest multiple expansion rather than a vaccine-style re-rating; risk/reward is attractive because downside is supported by core life-science demand.
• Pair long ILMN / short a basket of small-cap pandemic-theme biotech names for 3-6 months. The thesis is that procurement shifts toward proven platforms and away from speculative names that need a broad federal response to monetize; upside on the long is steady installed-base demand, while the short side is vulnerable to funding and narrative compression.
• Consider a tactical long in ABBV and MRNA only through defined-event option structures if outbreak headlines intensify. Buy 1-3 month calls or call spreads to express a volatility spike, but avoid outright equity exposure because misinformation risk can delay adoption even when demand appears obvious.
• Short-term hedge: buy protective puts on XBI into any outbreak-related rally. The sector can rally on preparedness headlines, but if the story stays contained the premium should bleed quickly; this is a cleaner expression than shorting diagnostics outright.
• Watch for local/state procurement announcements over the next 1-3 months; if they formalize stockpiles or testing contracts, rotate into regional healthcare distributors and lab service names before the broader market prices in decentralized spending.